Latest News in the pharma Industry
Research & Development
Ferring backs Foresee's SIF platform for controlled-release formulations
13 Feb 2017
Foresee technology can help to develop stable, formulated peptides in solution for controlled-release therapy for 3- and 6-month durations of action after a single injection.
Read more
Aquarium-to-bedside drug shows promise in small pediatric trial
12 Feb 2017
NIH-funded research suggests zebrafish models may be efficient resource for identifying drugs for clinical use.
Read more
First patient enrolled in Phase II study evaluating JZP-110 for excessive sleepiness in Parkinson's disease
12 Feb 2017
JZP-110 is a selective dopamine and norepinephrine reuptake inhibitor.
Read more
Afatinib to be evaluated in combination with pembrolizumab in new trial for patients with SqCC of the lung
9 Feb 2017
Boehringer Ingelheim to conduct trial in collaboration with a subsidiary of Merck (MSD).
Read more
Designer compound may untangle damage leading to some dementias
9 Feb 2017
NIH-funded preclinical study suggests a possible treatment for Alzheimer’s disease and other neurodegenerative disorders.
Read more
STA Pharma expands R&D team at is Changzhou site
6 Feb 2017
By the end of 2017, company plans to increase to 230 process chemists and 70 analytical chemists.
Read more
Amgen's Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study
6 Feb 2017
Landmark Repatha cardiovascular outcomes study meets primary and key secondary endpoint.
Read more
FDA accepts two sBLAs for Merck's Keytruda for metastatic urothelial cancer
5 Feb 2017
Keytruda also receives Breakthrough Therapy Designation for second-line treatment.
Read more
FDA approves BMS's Opdivo for bladder cancer
5 Feb 2017
Opdivo has now been approved in six tumour types in just over 2 years.
Read more
Merck gets the thumbs up in Europe for Keytruda to treat patients with metastatic NSCLC
2 Feb 2017
First anti-PD-1 therapy approved in Europe for previously untreated patients with metastatic NSCLC.
Read more
Novartis' Votubia receives EU approval to treat refractory partial-onset seizures in patients with TSC
31 Jan 2017
Decision marks the third TSC-related indication for Votubia in the EU.
Read more
FDA approves Allergan's sNDA for Avycaz to include new Phase III data in patients with cUTI
30 Jan 2017
New clinical data for Avycaz demonstrates efficacy in cUTI patients including those with infections due to resistant Gram-negative pathogens.
Read more